The committee noted that semaglutide tablets 3 mg, 7 mg, and 14 mg are approved for marketing in India. The firm has claimed ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of 16 pounds.

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

India’s weight loss category is undergoing a dynamic transformation triggered by scientific improvements, pharma innovation, and growing consumer demand ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years ...

However, Kim Ji-min "I lost weight, but my personality deteriorated." I'm so sensitive that I don't want to see you these ...

Tirzepatide was approved in November 2023 by the US Food and Drug Administration (FDA) (Zepbound) and in the EU in June 2024 ...

Victoza, produced by Novo Nordisk, holds FDA approval for regulating blood sugar levels among individuals diagnosed with type ...

The study, led by Dr Luca Busetto from the University of Padova in Italy and colleagues from Eli Lilly and Company that ...